Recent Advances Lead to a Breakthrough Method for Expanded Medical Use of Adult Stem Cells

GOLDEN, CO--(Marketwire - March 31, 2010) - Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced recent research results that reveal a simplified method for production of induced pluripotent stem cells or IPS cells. IPS technology allows the use of reprogrammed adult cells to achieve properties of embryonic stem cells including the ability to differentiate into any type of cell in the body. Many research groups focus specifically on IPS technology because it allows for the generation of stem cells with the primary properties of embryonic stem cells without sacrifice or use of embryos. Use of IPS technology completely avoids ethical and religious controversies surrounding the use of embryonic stem cells.

At a recent scientific symposium titled "Stem Cell Differentiation and Dedifferentiation," Vitro scientists presented their evidence that expression of a single gene within adult stem cells resulted in expanded differentiation capacity comparable to embryonic stem cells that have the capacity to differentiate into any cell of the body, called pluripotency. This significant advance in stem cell technology and the novel concept of single-factor control of pluripotency in adult stem cells was also supported by reports of two other prestigious scientific research institutions at this same symposium. Vitro has a patent application pending with the USPTO regarding its technology related to generation of IPS cells from adult stem cells.

Dr. Joe Nieusma, a member of Vitro's SAB, said, "These new findings by Vitro and other leading stem cell researchers represent a significant advance in stem cell science. Commercial production of stem cell-derived cell systems will enhance pharmaceutical testing for discovery, development and safety of drugs. Vast and sweeping improvements to the current state-of-the-art for personalized medicine should be achieved following the significant work of Vitro and other stem cell researchers. Numerous untreatable or under treated conditions such as diabetes, Alzheimer's disease, stroke, and spinal cord injury, just to name a few, now have shortened timelines to better therapies through stem cell technologies and these therapies are clearly in sight. We anticipate rapid expansion of our present product line especially targeting drug discovery and development based upon our recent breakthrough."

The original method to generate pluripotency involved genetic engineering of human skin cells to express elevated levels of four key genes. The new research reported at the symposium by three independent groups, including Vitro, showed that adult stem cells expressing increased levels of just a single gene, Oct-4, resulted in pluripotency. One likely explanation of these findings is that adult stem cells already contain increased expression levels of the other factors required for pluripotency. If this is the case, these cells could then be reprogrammed by elevating expression of the single gene, Oct-4. This gene is considered by many researchers to be a master gene in the regulation of pluripotency.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) (http://www.vitrobiopharma.com), owns US patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro also owns pending US patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™," including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.